Arvinas’ (ARVN) “Buy” Rating Reaffirmed at HC Wainwright

Arvinas (NASDAQ:ARVN)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research report issued on Monday,Benzinga reports. They presently have a $81.00 target price on the stock.

A number of other equities analysts have also weighed in on ARVN. Wedbush lowered Arvinas from an “outperform” rating to a “neutral” rating and lowered their target price for the stock from $57.00 to $12.00 in a research note on Wednesday, March 12th. BTIG Research assumed coverage on Arvinas in a report on Tuesday, December 10th. They set a “buy” rating and a $69.00 target price for the company. Citigroup reduced their target price on shares of Arvinas from $28.00 to $19.00 and set a “neutral” rating for the company in a research report on Friday, March 7th. Guggenheim lowered their price target on shares of Arvinas from $57.00 to $32.00 and set a “buy” rating on the stock in a research report on Thursday, March 13th. Finally, Wells Fargo & Company set a $26.00 price objective on shares of Arvinas and gave the company an “overweight” rating in a report on Wednesday, March 12th. Five analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, Arvinas currently has a consensus rating of “Moderate Buy” and an average target price of $35.50.

Arvinas Trading Down 2.8 %

ARVN opened at $6.19 on Monday. The stock’s fifty day simple moving average is $13.45 and its 200 day simple moving average is $19.64. Arvinas has a 1-year low of $6.00 and a 1-year high of $39.34. The stock has a market cap of $425.70 million, a PE ratio of -2.23 and a beta of 2.30.

Arvinas (NASDAQ:ARVN) last issued its quarterly earnings data on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same period last year, the firm earned ($2.53) EPS. Equities analysts forecast that Arvinas will post -3.81 earnings per share for the current year.

Insider Activity at Arvinas

In other Arvinas news, CEO John G. Houston sold 31,338 shares of the firm’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $16.72, for a total value of $523,971.36. Following the sale, the chief executive officer now owns 1,157,480 shares of the company’s stock, valued at approximately $19,353,065.60. This trade represents a 2.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Noah Berkowitz sold 8,658 shares of the business’s stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.59, for a total value of $74,372.22. Following the transaction, the insider now directly owns 110,023 shares of the company’s stock, valued at $945,097.57. This trade represents a 7.30 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 50,230 shares of company stock valued at $769,402 over the last three months. 5.23% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in ARVN. Rhumbline Advisers lifted its stake in Arvinas by 3.8% in the 1st quarter. Rhumbline Advisers now owns 91,210 shares of the company’s stock valued at $640,000 after purchasing an additional 3,333 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Arvinas by 11,283.8% in the 1st quarter. GAMMA Investing LLC now owns 4,212 shares of the company’s stock valued at $300,000 after acquiring an additional 4,175 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Arvinas during the 4th quarter valued at $28,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Arvinas by 0.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 433,531 shares of the company’s stock worth $8,311,000 after acquiring an additional 3,047 shares during the last quarter. Finally, Voloridge Investment Management LLC bought a new stake in Arvinas during the 4th quarter worth $749,000. Institutional investors own 95.19% of the company’s stock.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.